论文部分内容阅读
目的 观察新型乙型肝炎病毒(HBV)核心抗原(HBcAg)核酸疫苗的免疫原性。方法 应用新型人体应用载体质粒pSW3891构建HBcAg核酸疫苗(pSW3891/HBC),对照组和实验组Balb/c小鼠分别以基因枪法免疫对照载体质粒(pSW3891)和HBcAg核酸疫苗,采用酶联免疫吸附试验检测抗-HBc,乳酸脱氢酶(LDH)释放测定法检测小鼠HBcAg特异性CTL杀伤活性。结果 HBcAg核酸疫苗可在体外293T细胞中高效表达,免疫小鼠后可产生高滴度抗-HBc(1:97200),免疫鼠脾细胞HBc特异性CTL杀伤活性达73.25％。结论 新型HBcAg核酸疫苗在Balb/c小鼠实验中表现出良好的体液和细胞免疫原性。
Objective To observe the immunogenicity of novel hepatitis B virus (HBV) core antigen (HBcAg) nucleic acid vaccine. Methods HBcAg DNA vaccine (pSW3891 / HBC) was constructed by using a novel human plasmid pSW3891 and Balb / c mice in control group and control group were immunized with plasmid vector pSW3891 and HBcAg respectively by gene gun method. Enzyme-linked immunosorbent assay Detection of anti-HBc, lactate dehydrogenase (LDH) release assay mouse HBcAg-specific CTL killing activity. Results The HBcAg DNA vaccine could be efficiently expressed in 293T cells in vitro. High-titer anti-HBc (1: 97200) was produced in mice immunized with HBcAg. The cytotoxicity of HBc-specific CTLs to immunized mice was 73.25%. Conclusion The new HBcAg DNA vaccine showed good humoral and cellular immunogenicity in Balb / c mice.